Systematic review of 27 trials (3946 patients) with solid tumours: adding LAG-3 blockade raised grade 3–5 treatment-related adverse events (OR 1.79), adrenal insufficiency and arthralgia; adding TIGIT blockade raised any-grade rash (OR 2.32).
Meta-analysisn = 3,946
Fujiwara et al. Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis